Jaguar Gene Therapy
Two Conway Park, 150 North Field Drive
6 articles with Jaguar Gene Therapy
Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting
Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting.
Jaguar Gene Therapy Announces Preclinical Data Presentations at Upcoming American Society of Gene and Cell Therapy 25th Annual Meeting
Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced two abstracts related to its JAG101 Type 1 galactosemia program will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
Jaguar Gene Therapy announced Samsung Ventures, an investment corporation established to promote the development of new technologies, and the JDRF T1D Fund, a venture philanthropy fund devoted to finding and funding the best cure-oriented therapies for Type 1 diabetes, have invested in the company.
Jaguar Gene Therapy, today announced additional details, including target genes, for its initial preclinical pipeline programs: JAG101 for Type 1 galactosemia; JAG201 for a genetic cause of autism spectrum disorder (ASD) and Phelan-McDermid syndrome and other severe neurodevelopmental disorders with a SHANK3 mutation or deletion; and JAG301 for Type 1 diabetes.
The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.
Jaguar Gene Therapy Announces State-of-the-Art Gene Therapy Commercial Manufacturing Facility in North Carolina
Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, announced plans for a commercial manufacturing facility in Durham, North Carolina.